Aktuellt
SENASTE
Redeye has a relatively neutral stance on IRRAS’ Q4 report, with sales coming in under and costs above our forecasts. We highlight the commercial partnership with Medtronic and argue that it underpins the potential of IRRAflow. The biggest concern in the short term is the company’s cash position, and we expect an equity issue towards the end of H1 2023e.
LÄS MER
